Clinical Social Workers in Secaucus, NJ Accepting Medicare

6 Clinical Social Workers found. Showing 1 - 6

Helen H. Spencer-snyder, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 38 Meadowland Pkwy, Meadowlands Center For Counseling, Secaucus, NJ 07094 Phone: 781-526-1072

Alison Schwartz, LCSW, LCADC Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 595 County Ave Bldg 6, Secaucus, NJ 07094 Phone: 973-623-0600    Fax: 973-623-1862

Ms. Carole E Schwartz, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1138 Harmon Cove Tower, Apt 1138, Secaucus, NJ 07094 Phone: 201-805-1696    Fax: 201-553-9255

Alison Burks, LCSW, LCADC Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 595 County Ave Bldg 6, Secaucus, NJ 07094 Phone: 973-623-0600    Fax: 973-623-1862

Ziheng Song Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 120 Park Plaza Dr Apt 3424, Secaucus, NJ 07094 Phone: 212-729-0544

Michelle Jamsek, MSW, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 776 2nd St # 2, Secaucus, NJ 07094 Phone: 201-240-6161

News Archive

Novel ferritin nanoparticle vaccine candidate effective against SARS-CoV-2 variants in preclinical trials

A team of scientists from the United States has recently evaluated the efficacy of a ferritin nanoparticle-formulated, SARS-CoV-2 spike-based vaccine against newly emerged Variants of Concern (VOCs).

AlloSource, Wright Medical Group enter supply and distribution agreement for FUSIONFLEX graft

Wright Medical Group, a global orthopaedic medical device company, today announced a supply and distribution agreement with AlloSource for FUSIONFLEX™ Bone Matrix, a unique bone repair scaffold for use in primary fusion procedures of the foot and ankle, as well as other orthopaedic bone grafting applications.

Genzyme second-quarter revenue decreases to $1.08 billion

Genzyme Corp. today reported that second-quarter revenue was $1.08 billion, compared with $1.23 billion in the same period last year, reflecting limited shipments of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) due to product supply constraints in 2010. The company expects to be able to increase shipments of Cerezyme and Fabrazyme during the second half of the year.

New approach for understanding how drug resistance occurs in leukemia

UCSF researchers have developed a new approach to identify specific genes that influence how cancer cells respond to drugs and how they become resistant. This strategy, which involves producing diverse genetic mutations that result in leukemia and associating specific mutations with treatment outcomes, will enable researchers to better understand how drug resistance occurs in leukemia and other cancers, and has important long-term implications for the development of more effective therapies.

Read more Medical News

› Verified 6 days ago